<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="bdr22456" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Birth Defects Res</journal-id><journal-id journal-id-type="iso-abbrev">Birth Defects Res</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">BDR2</journal-id><journal-title-group><journal-title>Birth Defects Research</journal-title></journal-title-group><issn pub-type="epub">2472-1727</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11841020</article-id><article-id pub-id-type="pmcid-ver">PMC11841020.1</article-id><article-id pub-id-type="pmcaid">11841020</article-id><article-id pub-id-type="pmcaiid">11841020</article-id><article-id pub-id-type="pmid">39976348</article-id><article-id pub-id-type="doi">10.1002/bdr2.2456</article-id><article-id pub-id-type="publisher-id">BDR22456</article-id><article-id pub-id-type="other">BDR-24-0156.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Prenatal Opioid Use Disorder and the Risk of Congenital Anomalies in Offspring: A Population&#8208;Based Study</article-title></title-group><contrib-group><contrib id="bdr22456-cr-0001" contrib-type="author"><name name-style="western"><surname>Ramage</surname><given-names initials="K">Kaylee</given-names></name><xref rid="bdr22456-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bdr22456-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bdr22456-cr-0002" contrib-type="author"><name name-style="western"><surname>Yee</surname><given-names initials="J">Jennifer</given-names></name><xref rid="bdr22456-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="bdr22456-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="bdr22456-cr-0003" contrib-type="author"><name name-style="western"><surname>Srugo</surname><given-names initials="S">Sebastian</given-names></name><xref rid="bdr22456-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="bdr22456-cr-0004" contrib-type="author"><name name-style="western"><surname>Little</surname><given-names initials="J">Julian</given-names></name><xref rid="bdr22456-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="bdr22456-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shiliang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4496-0279</contrib-id><xref rid="bdr22456-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="bdr22456-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>shiliang.liu@phac-aspc.gc.ca</email></address></contrib></contrib-group><aff id="bdr22456-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Community Health Sciences</named-content>
<institution>University of Calgary</institution>
<city>Calgary</city>
<country country="CA">Canada</country>
</aff><aff id="bdr22456-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>School of Public Health, san Diego State University</institution>
<city>San Diego</city>
<country country="US">USA</country>
</aff><aff id="bdr22456-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Centre for Surveillance and Applied Research, Public Health Agency of Canada</institution>
<city>Ottawa</city>
<country country="CA">Canada</country>
</aff><aff id="bdr22456-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">School of Epidemiology and Public Health</named-content>
<institution>University of Ottawa</institution>
<city>Ottawa</city>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Shiliang Liu (<email>shiliang.liu@phac-aspc.gc.ca</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2025</year></pub-date><volume>117</volume><issue seq="190">2</issue><issue-id pub-id-type="pmc-issue-id">482565</issue-id><issue-id pub-id-type="doi">10.1002/bdr2.v117.2</issue-id><elocation-id>e2456</elocation-id><history><date date-type="rev-recd"><day>16</day><month>1</month><year>2025</year></date><date date-type="received"><day>13</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>21</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-23 11:25:28.793"><day>23</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Birth Defects Research</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BDR2-117-e2456.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BDR2-117-e2456.pdf"/><abstract><title>ABSTRACT</title><sec id="bdr22456-sec-0001"><title>Objective</title><p>To examine whether prenatal opioid use disorder (OUD) diagnosis is associated with the risk of congenital anomalies (CAs) in offspring.</p></sec><sec id="bdr22456-sec-0002"><title>Methods</title><p>We conducted a population&#8208;based study of mother&#8211;newborn dyads comprising.</p><p>4143 761 births delivered in Canada from 2006 to 2021. We used robust Poisson regression to examine the association between prenatal OUD diagnosis and risk of non&#8208;chromosomal CAs, adjusted for maternal age, parity, multiple gestation, co&#8208;morbidities (including mental health disorders, chronic illnesses and other substance use disorders), and infant sex.</p></sec><sec id="bdr22456-sec-0003"><title>Results</title><p>We identified a total of 21, 638 births to persons who were diagnosed with prenatal OUD and 65, 992 (159.3 per 10,000) newborns with CAs. The overall risk of CAs was 2.3 times higher in infants born to birthing persons with a diagnosis of OUD (95% CI 2.2, 2.5). Compared to those without OUD diagnoses, births to persons with a diagnosis of OUD had a higher risk of specific types of congenital microcephaly (aRR 5.2, 95% CI 4.1, 6.6), cleft palate (RR 4.8, 95% CI 3.7, 6.1), pulmonary valve atresia with intact ventricular septum (aRR 2.7, 95% CI 1.1, 6.7), and atrial septal defect (aRR 3.1, 95% CI 2.8, 3.5), among others. In particular, infants born to those with an OUD diagnosis had a 1.8 (95% CI 1.4, 2.3)&#8208;fold increased risk of having severe congenital heart disease.</p></sec><sec id="bdr22456-sec-0004"><title>Conclusion</title><p>Our findings suggest an association between prenatal OUD diagnosis and certain CAs in the offspring. Future research is necessary to better understand the role of socio&#8208;demographic factors on these associations.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bdr22456-kwd-0001">birth defects</kwd><kwd id="bdr22456-kwd-0002">congenital anomaly</kwd><kwd id="bdr22456-kwd-0003">congenital heart disease</kwd><kwd id="bdr22456-kwd-0004">congenital microcephaly</kwd><kwd id="bdr22456-kwd-0005">opioid use</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="8"/><word-count count="5500"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:20.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="bdr22456-ntgp-0001"><fn fn-type="funding" id="bdr22456-note-0001"><p>
<bold>Funding:</bold> This study was supported by the Public Health Agency of Canada's Enhanced Surveillance for Chronic Disease Program (2022&#8208;SR013). Dr. Little holds a University of Ottawa Distinguished Research Chair in Chronic Disease Epidemiology and Control. During this research, Dr. Ramage held a Canadian Institute of Health Research (CIHR) Post&#8208;Doctoral Research Fellowship.</p></fn></fn-group></notes></front><body id="bdr22456-body-0001"><sec sec-type="background" id="bdr22456-sec-0005"><label>1</label><title>Background</title><p>Perinatal maternal substance use has become of significant public health importance, particularly in view of changes in substance use policy and the high level of morbidity and mortality related to opioid use in Canada (Fischer&#160;<xref rid="bdr22456-bib-0007" ref-type="bibr">2023</xref>). Given their increasing use in the Canadian population, the effects of prenatal opioid exposure on fetal and child development are of particular concern.</p><p>Opioid use in Canada has been steadily increasing in the general population (Belzak and Halverson&#160;<xref rid="bdr22456-bib-0001" ref-type="bibr">2018</xref>). Data from the 2019 Canadian Alcohol and Drugs Survey revealed that 14% of Canadians aged 15&#8201;years and older reported having used opioids in the previous year compared to 12% reported in 2017 (Health Canada&#160;<xref rid="bdr22456-bib-0009" ref-type="bibr">2021</xref>). Increasing opioid use has also been reported in pregnant populations in Canada (Corsi et&#160;al.&#160;<xref rid="bdr22456-bib-0006" ref-type="bibr">2020</xref>). An examination of opioid&#8208;dependent women in Ontario, Canada between 2002 and 2014 found that the number of infants born to women with opioid abuse and dependence had increased from 46 to 800 per year during this time (Brogly et&#160;al.&#160;<xref rid="bdr22456-bib-0003" ref-type="bibr">2017</xref>). Similarly, an analysis of labor and delivery hospitalizations in the U.S.A. from 2010 to 2017 showed an increase in maternal opioid&#8208;related diagnosis rates at delivery from 3.5 per 1000 hospitalizations in 2010 to 8.2 per 1000 hospitalizations in 2017 (Hirai et&#160;al.&#160;<xref rid="bdr22456-bib-0010" ref-type="bibr">2021</xref>).</p><p>Opioid use in pregnancy has been associated with a variety of adverse outcomes for the developing fetus, including structural effects within the brain, neonatal abstinence syndrome (NAS), preterm birth, low birthweight, and small&#8208;for&#8208;gestational&#8208;age births (Corsi et&#160;al.&#160;<xref rid="bdr22456-bib-0006" ref-type="bibr">2020</xref>; Merhar et&#160;al.&#160;<xref rid="bdr22456-bib-0018" ref-type="bibr">2021</xref>; N&#248;rgaard et&#160;al.&#160;<xref rid="bdr22456-bib-0020" ref-type="bibr">2015</xref>; Patrick et&#160;al.&#160;<xref rid="bdr22456-bib-0022" ref-type="bibr">2015</xref>; Turner et&#160;al.&#160;<xref rid="bdr22456-bib-0031" ref-type="bibr">2015</xref>). Furthermore, prenatal opioid exposure has been reported to be associated with several types of congenital anomalies (CAs) (Viteri et&#160;al.&#160;<xref rid="bdr22456-bib-0032" ref-type="bibr">2015</xref>). A 2017 systematic review (Lind et&#160;al.&#160;<xref rid="bdr22456-bib-0013" ref-type="bibr">2017</xref>) of 68 studies found that prenatal opioid exposure was associated with higher rates of oral clefts, ventricular septal defects, atrial septal defects, and clubfoot; however, the authors noted that considerable uncertainty remains regarding the teratogenicity of opioids given the variability in study design, poor data quality, and inadequate consideration of potential confounders in the included studies. One ecological study also found an association between opioid prescription rates and trends in gastroschisis (Short&#160;<xref rid="bdr22456-bib-0028" ref-type="bibr">2019</xref>).</p><p>Given that the growing rate of prenatal opioid use disorder (OUD) in the Canadian population is of public health concern, it is important to investigate the relationship of this exposure to CAs and to provide population&#8208;based evidence to fill existing gaps in the literature. To respond to this need, we assessed the association between prenatal OUD diagnosis and the risk of CAs in Canada.</p></sec><sec sec-type="methods" id="bdr22456-sec-0006"><label>2</label><title>Methods</title><p>This study adheres to the STROBE reporting guidelines. Using data from the Discharge Abstract Database (DAD), we conducted a population&#8208;based analysis of livebirths and stillbirths (including late pregnancy terminations) occurring in hospitals in Canada (excluding Quebec) between April 1, 2006 to March 31, 2021. The DAD is maintained by the Canadian Institute for Health Information (CIHI) and includes records of hospital labor and delivery for all mothers and babies at &#8805;&#8201;20&#8201;weeks gestation in Canada (excluding Quebec). Within CIHI, the DAD records are collated by trained medical record personnel using standardized definitions and include information on maternal and newborn characteristics (e.g., gestational age, plurality, birthweight) and maternal and newborn diagnoses (up to 25 diagnostic fields) and interventions (up to 20 procedure fields) noted during the labor and delivery hospitalization. Validation studies have shown data from the DAD to have high sensitivity and specificity in the coding of major perinatal procedures and outcomes (Joseph et&#160;al.&#160;<xref rid="bdr22456-bib-0011" ref-type="bibr">2009</xref>), especially CAs (Public Health Agency of Canada&#160;<xref rid="bdr22456-bib-0025" ref-type="bibr">2013</xref>), and this database has previously been used for perinatal research (Liu et&#160;al.&#160;<xref rid="bdr22456-bib-0014" ref-type="bibr">2021</xref>; Plouffe et&#160;al.&#160;<xref rid="bdr22456-bib-0024" ref-type="bibr">2023</xref>; Ramage et&#160;al.&#160;<xref rid="bdr22456-bib-0026" ref-type="bibr">2019</xref>).</p><p>Liveborn infants were linked to maternal medical records using a unique, CIHI&#8208;assigned maternal&#8208;newborn identifier. Stillbirths (including late&#8208;term pregnancy terminations) were linked through a previously validated algorithm (Liu et&#160;al.&#160;<xref rid="bdr22456-bib-0015" ref-type="bibr">2019</xref>) to the maternal childbirth medical records. Maternal and infant characteristics were captured in the DAD, including maternal age (categorized as &lt;&#8201;20&#8201;years, 20&#8211;24&#8201;years, 25&#8211;29&#8201;years, 30&#8211;34&#8201;years, 35&#8211;39&#8201;years, and 40&#8211;49&#8201;years), parity (categorized as first, second, third, or higher order child, and missing values), newborn sex, residence (rural vs. urban), chronic conditions or illnesses, prenatal use of other specified/unspecified drugs or medications (e.g., alcohol, tobacco, and psychostimulants), pregestational diabetes mellitus, and maternal non&#8208;chromosomal anomalies; these were included in the analysis as covariates (Liu et&#160;al.&#160;<xref rid="bdr22456-bib-0016" ref-type="bibr">2015</xref>). To account for non&#8208;independence in the dataset (i.e., multiple deliveries by the same birthing person over the study period), we included only the first delivery in the dataset for each birthing person.</p><p>The full list of International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Canadian edition (ICD&#8208;10&#8208;CA) codes used to classify maternal and infant exposures are available in Tables&#160;<xref rid="bdr22456-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="bdr22456-supitem-0001" ref-type="supplementary-material">S2</xref>, respectively. Birthing persons with a diagnosis of prenatal OUD were identified by maternal codes F11 (opioid&#8208;related disorders), T40.0 (poisoning by, adverse effect of, and underdosing of narcotics and psychodysleptics), or R78.1 (finding of opioid in blood) or newborn code P96.1 (neonatal withdrawal symptoms from maternal use of drugs of addiction or &#8220;neonatal abstinence syndrome&#8221;), which aligns with other indicators of prenatal opioid use using the DAD (Camden et&#160;al.&#160;<xref rid="bdr22456-bib-0004" ref-type="bibr">2021</xref>). Diabetes mellitus, maternal pain&#8208;related diseases, and major CAs were included in the analysis as covariates. Maternal conditions/illnesses were coded using the ICD&#8208;10&#8208;CA, including lupus, epilepsy, migraine, severe obesity, and use of other substances. CAs in infants (up to 1&#8201;year old) identified after birth hospital discharge through a pre&#8208;verified follow&#8208;up linkage algorithm were added to the birth outcome (Liu and Wen&#160;<xref rid="bdr22456-bib-0017" ref-type="bibr">1999</xref>).</p><p>Diagnoses of CAs among newborns were also coded using the ICD&#8208;10&#8208;CA, including those of the central nervous system (i.e., neural tube defects, microcephaly), heart, kidney (i.e., renal agenesis, cystic kidney disease), and so on. Newborns with Down syndrome and other chromosomal anomalies (<italic toggle="yes">n</italic>&#8201;=&#8201;9129) identified were excluded from the analysis. A full description of the ICD&#8208;10&#8208;CA codes used is presented in Table&#160;<xref rid="bdr22456-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><p>We first conducted descriptive statistics to calculate the prevalence of newborns with CAs by maternal characteristics. The prevalence of specific CAs was expressed as the number of cases per 10,000 births. For opioid&#8208;exposed newborn groups, we estimated the crude and adjusted risk ratios (aRRs) with 95% confidence intervals (CIs) for each selected type of CAs using a Poisson distribution with robust standard error estimates to facilitate model convergence. In our multivariable analyses, we adjusted for covariates including maternal age, parity, multiple birth, infant sex, co&#8208;morbidities (e.g., lupus, migraine, obesity, maternal chronic conditions including lupus, migraine, arthritis, or cancer (as a proxy for pain management)), maternal mental health disorders (mood or anxiety disorder, bipolar disorder, schizophrenia), rural (versus urban) residence, and maternal use of other substances or drugs including tobacco, alcohol, cannabinoids, psychostimulants, and other illicit drugs. Each specific type of CA was estimated individually using a crude risk ratio and aRRs using multivariate regression.</p><p>Analyses were also conducted to examine issues related to the robustness of the results to unmeasured confounding using E&#8208;value methodology (Van der and Ding,&#160;<xref rid="bdr22456-bib-0034" ref-type="bibr">2017</xref>). The E&#8208;value is a measure related to evidence for causality and represents the minimum strength of association that an unmeasured confounder would need to have with both a fetal exposure and birth with a CA, conditional on the confounders in the regression model, to fully explain the observed association (Van der and Ding,&#160;<xref rid="bdr22456-bib-0034" ref-type="bibr">2017</xref>).</p></sec><sec sec-type="results" id="bdr22456-sec-0007"><label>3</label><title>Results</title><p>Our study population comprised 4,143,761 deliveries, including first live births or stillbirths delivered at &#8805;&#8201;22&#8201;weeks' gestation at hospitals in Canada (except Quebec) from fiscal year 2006/07 to 2020/21. Table&#160;<xref rid="bdr22456-tbl-0001" ref-type="table">1</xref> describes the characteristics of our study population. Overall, 0.52% of deliveries in our sample were to birthing persons with OUD diagnoses (<italic toggle="yes">n</italic>&#8201;=&#8201;21, 638). Compared to those without diagnosed opioid used disorder, birthing persons diagnosed with OUD were younger and had higher levels of concurrent mental health disorders (6.7% vs. 0.9%), tobacco use disorder (3.9% vs. 0.5%), alcohol use disorder (2.6% vs. 0.1%), and use of psychostimulants (10.9% vs. 0.1%). Over the study period, the proportion of deliveries to birthing persons with diagnosed OUD increased (20.5% occurred between 2006 and 2011 compared to 41.9% between 2016 and 2021) compared to the relatively constant proportion of deliveries to those without diagnosed prenatal OUD over the study period.</p><table-wrap position="float" id="bdr22456-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics according to presence of prenatal opioid use disorder (OUD) diagnosis in Canada excluding Quebec, 2006&#8211;2021.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" colspan="2" valign="bottom" rowspan="1">Birthing person diagnosed with OUD (%)</th><th align="center" colspan="2" valign="bottom" rowspan="1">Birthing person not diagnosed with OUD (%)</th></tr></thead><tbody valign="top"><tr style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">21,638</td><td align="center" valign="top" rowspan="1" colspan="1">100.0</td><td align="center" valign="top" rowspan="1" colspan="1">4,122,123</td><td align="center" valign="top" rowspan="1" colspan="1">100.0</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Age at delivery (year)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&lt;&#8201;20</td><td align="center" valign="top" rowspan="1" colspan="1">916</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td><td align="center" valign="top" rowspan="1" colspan="1">136,445</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">20&#8211;24</td><td align="center" valign="top" rowspan="1" colspan="1">4937</td><td align="center" valign="top" rowspan="1" colspan="1">22.8</td><td align="center" valign="top" rowspan="1" colspan="1">542,957</td><td align="center" valign="top" rowspan="1" colspan="1">13.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">25&#8211;29</td><td align="center" valign="top" rowspan="1" colspan="1">7151</td><td align="center" valign="top" rowspan="1" colspan="1">33.1</td><td align="center" valign="top" rowspan="1" colspan="1">1,163,965</td><td align="center" valign="top" rowspan="1" colspan="1">28.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">30&#8211;34</td><td align="center" valign="top" rowspan="1" colspan="1">5633</td><td align="center" valign="top" rowspan="1" colspan="1">26.0</td><td align="center" valign="top" rowspan="1" colspan="1">1,407,261</td><td align="center" valign="top" rowspan="1" colspan="1">34.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">35&#8211;49</td><td align="center" valign="top" rowspan="1" colspan="1">3001</td><td align="center" valign="top" rowspan="1" colspan="1">13.9</td><td align="center" valign="top" rowspan="1" colspan="1">871,495</td><td align="center" valign="top" rowspan="1" colspan="1">21.1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Parity</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1st child</td><td align="center" valign="top" rowspan="1" colspan="1">8128</td><td align="center" valign="top" rowspan="1" colspan="1">37.6</td><td align="center" valign="top" rowspan="1" colspan="1">1,466,783</td><td align="center" valign="top" rowspan="1" colspan="1">35.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2nd child</td><td align="center" valign="top" rowspan="1" colspan="1">5281</td><td align="center" valign="top" rowspan="1" colspan="1">24.4</td><td align="center" valign="top" rowspan="1" colspan="1">1,131,935</td><td align="center" valign="top" rowspan="1" colspan="1">27.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;&#8201;3rd child</td><td align="center" valign="top" rowspan="1" colspan="1">3493</td><td align="center" valign="top" rowspan="1" colspan="1">16.1</td><td align="center" valign="top" rowspan="1" colspan="1">729,204</td><td align="center" valign="top" rowspan="1" colspan="1">17.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing data<xref rid="bdr22456-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4736</td><td align="center" valign="top" rowspan="1" colspan="1">21.9</td><td align="center" valign="top" rowspan="1" colspan="1">794,201</td><td align="center" valign="top" rowspan="1" colspan="1">19.3</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Multiple birth</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">431</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">118,959</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">21,207</td><td align="center" valign="top" rowspan="1" colspan="1">98.0</td><td align="center" valign="top" rowspan="1" colspan="1">4,006,164</td><td align="center" valign="top" rowspan="1" colspan="1">97.1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Infant sex</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">11,654</td><td align="center" valign="top" rowspan="1" colspan="1">53.9</td><td align="center" valign="top" rowspan="1" colspan="1">2,113, 412</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">9984</td><td align="center" valign="top" rowspan="1" colspan="1">46.1</td><td align="center" valign="top" rowspan="1" colspan="1">2,008,711</td><td align="center" valign="top" rowspan="1" colspan="1">48.7</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Mental health disorder<xref rid="bdr22456-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">1446</td><td align="center" valign="top" rowspan="1" colspan="1">6.7</td><td align="center" valign="top" rowspan="1" colspan="1">35,827</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">20,192</td><td align="center" valign="top" rowspan="1" colspan="1">93.3</td><td align="center" valign="top" rowspan="1" colspan="1">4,086,296</td><td align="center" valign="top" rowspan="1" colspan="1">99.1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Substance use disorder</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Tobacco</td><td align="center" valign="top" rowspan="1" colspan="1">845</td><td align="center" valign="top" rowspan="1" colspan="1">3.9</td><td align="center" valign="top" rowspan="1" colspan="1">20,937</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alcohol</td><td align="center" valign="top" rowspan="1" colspan="1">545</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">4194</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Psychostimulants<xref rid="bdr22456-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2359</td><td align="center" valign="top" rowspan="1" colspan="1">10.9</td><td align="center" valign="top" rowspan="1" colspan="1">4568</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Miscellaneous<xref rid="bdr22456-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3791</td><td align="center" valign="top" rowspan="1" colspan="1">17.5</td><td align="center" valign="top" rowspan="1" colspan="1">124,979</td><td align="center" valign="top" rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Maternal chronic condition or illness</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="top" rowspan="1" colspan="1">78</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td><td align="center" valign="top" rowspan="1" colspan="1">4718</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lupus</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td><td align="center" valign="top" rowspan="1" colspan="1">3357</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pre&#8208;gestational diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">156</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">11,379</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Severe obesity</td><td align="center" valign="top" rowspan="1" colspan="1">436</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">75,884</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Migraine</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td><td align="center" valign="top" rowspan="1" colspan="1">1354</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other pain&#8208;related diagnoses<xref rid="bdr22456-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">160</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">18,188</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Maternal residence</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rural</td><td align="center" valign="top" rowspan="1" colspan="1">5014</td><td align="center" valign="top" rowspan="1" colspan="1">23.3</td><td align="center" valign="top" rowspan="1" colspan="1">668,609</td><td align="center" valign="top" rowspan="1" colspan="1">16.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Urban</td><td align="center" valign="top" rowspan="1" colspan="1">16,624</td><td align="center" valign="top" rowspan="1" colspan="1">76.7</td><td align="center" valign="top" rowspan="1" colspan="1">3,453,514</td><td align="center" valign="top" rowspan="1" colspan="1">83.8</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Birth period</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2006/07&#8211;2010/11</td><td align="center" valign="top" rowspan="1" colspan="1">4443</td><td align="center" valign="top" rowspan="1" colspan="1">20.5</td><td align="center" valign="top" rowspan="1" colspan="1">1,356,178</td><td align="center" valign="top" rowspan="1" colspan="1">32.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2011/12&#8211;2015/16</td><td align="center" valign="top" rowspan="1" colspan="1">8127</td><td align="center" valign="top" rowspan="1" colspan="1">37.6</td><td align="center" valign="top" rowspan="1" colspan="1">1,395,957</td><td align="center" valign="top" rowspan="1" colspan="1">33.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2016/17&#8211;2020/21</td><td align="center" valign="top" rowspan="1" colspan="1">9068</td><td align="center" valign="top" rowspan="1" colspan="1">41.9</td><td align="center" valign="top" rowspan="1" colspan="1">1,369,988</td><td align="center" valign="top" rowspan="1" colspan="1">33.2</td></tr></tbody></table><table-wrap-foot id="bdr22456-ntgp-0002"><fn id="bdr22456-note-0002"><label>
<sup>a</sup>
</label><p>Missing values for parity are treated as a specific category rather than imputing data.</p></fn><fn id="bdr22456-note-0003"><label>
<sup>b</sup>
</label><p>Depression, stress, anxiety, bipolar disorder, schizophrenia, delusional disorder, and personality disorders.</p></fn><fn id="bdr22456-note-0004"><label>
<sup>c</sup>
</label><p>Psychostimulants include cocaine and other stimulants.</p></fn><fn id="bdr22456-note-0005"><label>
<sup>d</sup>
</label><p>Includes inhalant, cannabinoids, psychoactive, or psychotropic substances and unspecified drugs.</p></fn><fn id="bdr22456-note-0006"><label>
<sup>e</sup>
</label><p>Arthritis, cancer, or major birth defects.</p></fn></table-wrap-foot></table-wrap><p>Table&#160;<xref rid="bdr22456-tbl-0002" ref-type="table">2</xref> describes the association between prenatal OUD diagnosis and CAs. Overall, 1.59% of infants were diagnosed with at least one type of CA (<italic toggle="yes">n</italic>&#8201;=&#8201;65, 992), yielding an overall prevalence of 159.3 per 10, 000 births. Atrial septal defect was the most common type of CAs (59.6 per 10,000 births), followed by ventricular septal defect (32.8 per 10,000 births) and hypospadias (30.2 per 10,000 births). All other CAs examined in this study had risks less than 10 cases per 10, 000 births. Compared to infants born to birthing persons who were not diagnosed with OUD, those infants born to birthing persons with diagnosed OUD were 2.34 times (95% CI: 2.19, 2.56) as likely to have a CA. aRRs were highest for congenital microcephaly (aRR: 5.20, 95% CI: 4.08, 6.62), cleft palate (aRR: 4.76, 95% CI: 3.71, 6.11), and atrial septal defect (aRR: 3.14, 95% CI: 2.84, 3.47). As well, those infants born to birthing persons with diagnosed prenatal OUD were also significantly more likely to have neural tube defects (aRR: 1.63, 95% CI: 1.11&#8211;2.40), coarctation of the aorta (aRR: 2.22, 95% CI: 1.50, 3.38), Tetralogy of Fallot (aRR: 1.97, 95% CI: 1.23&#8211;3.16), pulmonary valve atresia with intact ventricular septum (aRR: 2.67, 95% CI: 1.06, 6.70), left ventricular outflow tract obstruction (aRR: 2.01, 95% CI: 1.45&#8211;2.78), conotruncal defect (aRR: 1.87, 95% CI: 1.35&#8211;2.60), ventricular septal defect (aRR: 2.51, 95% CI: 2.16, 2.92), gastroschisis (aRR: 1.34, 95% CI: 1.22, 2.20), cystic kidney disease (aRR: 1.90, 95% CI: 1.33, 2.74), and hypospadias (aRR: 1.23, 95% CI:1.03, 1.50).</p><table-wrap position="float" id="bdr22456-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Association between prenatal opioid use disorder (OUD) diagnosis and selected congenital anomalies in Canada excluding Quebec, 2006&#8211;2021.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Type or subtype of anomaly</th><th align="center" colspan="2" valign="bottom" rowspan="1">Total</th><th align="center" colspan="2" valign="bottom" rowspan="1">Delivery to birthing person diagnosed with OUD (<italic toggle="yes">N</italic>&#8201;=&#8201;21,638)</th><th align="center" colspan="2" valign="bottom" rowspan="1">Delivery to birthing person not diagnosed with OUD (<italic toggle="yes">N</italic>&#8201;=&#8201;4,122,123)</th><th align="center" colspan="2" valign="bottom" rowspan="1">Risk ratio (RR, 95% CI)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Total N</th><th align="center" valign="bottom" rowspan="1" colspan="1">Per 10,000</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total N</th><th align="center" valign="bottom" rowspan="1" colspan="1">Risk per 10,000 total births</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total N</th><th align="center" valign="bottom" rowspan="1" colspan="1">Risk per 10,000 total births</th><th align="center" valign="bottom" rowspan="1" colspan="1">Unadjusted</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted<xref rid="bdr22456-note-0007" ref-type="table-fn">*</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">All specified anomalies</td><td align="center" valign="top" rowspan="1" colspan="1">65,992</td><td align="center" valign="top" rowspan="1" colspan="1">159.3</td><td align="center" valign="top" rowspan="1" colspan="1">957</td><td align="center" valign="top" rowspan="1" colspan="1">442.3</td><td align="center" valign="top" rowspan="1" colspan="1">65,035</td><td align="center" valign="top" rowspan="1" colspan="1">157.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.80 (2.63&#8211;2.99)</td><td align="center" valign="top" rowspan="1" colspan="1">2.34 (2.19&#8211;2.50)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neural tube defects</td><td align="center" valign="top" rowspan="1" colspan="1">3207</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td><td align="center" valign="top" rowspan="1" colspan="1">2998</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.84 (1.28&#8211;2.66)</td><td align="center" valign="top" rowspan="1" colspan="1">1.63 (1.11&#8211;2.40)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Congenital microcephaly</td><td align="center" valign="top" rowspan="1" colspan="1">2323</td><td align="center" valign="top" rowspan="1" colspan="1">5.6</td><td align="center" valign="top" rowspan="1" colspan="1">93</td><td align="center" valign="top" rowspan="1" colspan="1">43.0</td><td align="center" valign="top" rowspan="1" colspan="1">2230</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td><td align="center" valign="top" rowspan="1" colspan="1">7.94 (4.46&#8211;9.78)</td><td align="center" valign="top" rowspan="1" colspan="1">5.20 (4.08&#8211;6.62)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Critical congenital heart defects</td><td align="center" valign="top" rowspan="1" colspan="1">7561</td><td align="center" valign="top" rowspan="1" colspan="1">18.2</td><td align="center" valign="top" rowspan="1" colspan="1">80</td><td align="center" valign="top" rowspan="1" colspan="1">37.0</td><td align="center" valign="top" rowspan="1" colspan="1">7481</td><td align="center" valign="top" rowspan="1" colspan="1">18.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.04 (1.63&#8211;2.54)</td><td align="center" valign="top" rowspan="1" colspan="1">1.79 (1.42&#8211;2.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypoplastic left heart syndrome (HLHS)</td><td align="center" valign="top" rowspan="1" colspan="1">904</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td><td align="center" valign="top" rowspan="1" colspan="1">895</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.52 (1.77&#8211;3.59)</td><td align="center" valign="top" rowspan="1" colspan="1">1.79 (0.89&#8211;2.53)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Coarctation of the aorta (CoA)</td><td align="center" valign="top" rowspan="1" colspan="1">2364</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">12.9</td><td align="center" valign="top" rowspan="1" colspan="1">2336</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.92 (0.99&#8211;3.69)</td><td align="center" valign="top" rowspan="1" colspan="1">2.22 (1.50&#8211;3.38)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aortic valve stenosis (AoS)</td><td align="center" valign="top" rowspan="1" colspan="1">695</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">689</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.66 (0.74&#8211;3.71)</td><td align="center" valign="top" rowspan="1" colspan="1">1.18 (0.50&#8211;2.81)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tetralogy of Fallot (TOF)</td><td align="center" valign="top" rowspan="1" colspan="1">1723</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">8.8</td><td align="center" valign="top" rowspan="1" colspan="1">1704</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.12 (1.35&#8211;3.34)</td><td align="center" valign="top" rowspan="1" colspan="1">1.97 (1.23&#8211;3.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">d&#8208;transposition of great arteries (DTGA)</td><td align="center" valign="top" rowspan="1" colspan="1">1313</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">1302</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (0.89&#8211;2.91)</td><td align="center" valign="top" rowspan="1" colspan="1">1.50 (0.81&#8211;2.77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Double outlet right ventricle</td><td align="center" valign="top" rowspan="1" colspan="1">885</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">879</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (0.58&#8211;2.90)</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.45&#8211;2.41)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Persistent truncus arteriosus (PTA)</td><td align="center" valign="top" rowspan="1" colspan="1">377</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">372</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">3.11 (0.99&#8211;9.72)</td><td align="center" valign="top" rowspan="1" colspan="1">2.67 (1.06&#8211;6.70)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total anomalous pulmonary venous return (TAPVR)</td><td align="center" valign="top" rowspan="1" colspan="1">471</td><td align="center" valign="top" rowspan="1" colspan="1">1.1</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">465</td><td align="center" valign="top" rowspan="1" colspan="1">1.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.52 (1.04&#8211;6.08)</td><td align="center" valign="top" rowspan="1" colspan="1">1.74 (0.73&#8211;6.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Left ventricular outflow tract obstruction (LVOTO)</td><td align="center" valign="top" rowspan="1" colspan="1">3469</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1">18.0</td><td align="center" valign="top" rowspan="1" colspan="1">3430</td><td align="center" valign="top" rowspan="1" colspan="1">8.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.31 (1.47&#8211;2.76)</td><td align="center" valign="top" rowspan="1" colspan="1">2.01 (1.45&#8211;2.78)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conotruncal defect</td><td align="center" valign="top" rowspan="1" colspan="1">3699</td><td align="center" valign="top" rowspan="1" colspan="1">8.9</td><td align="center" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1">18.0</td><td align="center" valign="top" rowspan="1" colspan="1">3660</td><td align="center" valign="top" rowspan="1" colspan="1">8.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.03 (1.48&#8211;2.78)</td><td align="center" valign="top" rowspan="1" colspan="1">1.87 (1.35&#8211;2.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Right ventricular outflow tract obstruction (RVOTO)</td><td align="center" valign="top" rowspan="1" colspan="1">602</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">596</td><td align="center" valign="top" rowspan="1" colspan="1">1.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.92 (0.86&#8211;4.29)</td><td align="center" valign="top" rowspan="1" colspan="1">1.80 (0.78&#8211;4.18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ventricular septal defect (VSD)</td><td align="center" valign="top" rowspan="1" colspan="1">13,579</td><td align="center" valign="top" rowspan="1" colspan="1">32.8</td><td align="center" valign="top" rowspan="1" colspan="1">200</td><td align="center" valign="top" rowspan="1" colspan="1">92.4</td><td align="center" valign="top" rowspan="1" colspan="1">13,379</td><td align="center" valign="top" rowspan="1" colspan="1">32.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.85 (2.48&#8211;3.27)</td><td align="center" valign="top" rowspan="1" colspan="1">2.51 (2.16&#8211;2.92)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Atrial septal defect (ASD)</td><td align="center" valign="top" rowspan="1" colspan="1">24,682</td><td align="center" valign="top" rowspan="1" colspan="1">59.6</td><td align="center" valign="top" rowspan="1" colspan="1">460</td><td align="center" valign="top" rowspan="1" colspan="1">212.6</td><td align="center" valign="top" rowspan="1" colspan="1">24,222</td><td align="center" valign="top" rowspan="1" colspan="1">59.9</td><td align="center" valign="top" rowspan="1" colspan="1">3.62 (3.30&#8211;3.97)</td><td align="center" valign="top" rowspan="1" colspan="1">3.14 (2.84&#8211;3.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gastroschisis</td><td align="center" valign="top" rowspan="1" colspan="1">1436</td><td align="center" valign="top" rowspan="1" colspan="1">3.5</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">7.9</td><td align="center" valign="top" rowspan="1" colspan="1">1419</td><td align="center" valign="top" rowspan="1" colspan="1">3.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.24 (1.39&#8211;3.61)</td><td align="center" valign="top" rowspan="1" colspan="1">1.34 (1.22&#8211;2.20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cystic kidney disease</td><td align="center" valign="top" rowspan="1" colspan="1">2991</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">15.3</td><td align="center" valign="top" rowspan="1" colspan="1">2958</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.13 (1.51&#8211;3.00)</td><td align="center" valign="top" rowspan="1" colspan="1">1.90 (1.33&#8211;2.74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cleft palate</td><td align="center" valign="top" rowspan="1" colspan="1">2746</td><td align="center" valign="top" rowspan="1" colspan="1">6.6</td><td align="center" valign="top" rowspan="1" colspan="1">78</td><td align="center" valign="top" rowspan="1" colspan="1">36.0</td><td align="center" valign="top" rowspan="1" colspan="1">2668</td><td align="center" valign="top" rowspan="1" colspan="1">6.5</td><td align="center" valign="top" rowspan="1" colspan="1">5.57 (4.45&#8211;6.98)</td><td align="center" valign="top" rowspan="1" colspan="1">4.76 (3.71&#8211;6.11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cleft lip &#177; cleft palate</td><td align="center" valign="top" rowspan="1" colspan="1">3943</td><td align="center" valign="top" rowspan="1" colspan="1">9.5</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td><td align="center" valign="top" rowspan="1" colspan="1">3914</td><td align="center" valign="top" rowspan="1" colspan="1">9.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.41 (0.98&#8211;2.03)</td><td align="center" valign="top" rowspan="1" colspan="1">1.11 (0.76&#8211;1.63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Esophageal atresia &#177; tracheoesophageal fistula</td><td align="center" valign="top" rowspan="1" colspan="1">1122</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td><td align="center" valign="top" rowspan="1" colspan="1">1109</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">2.23 (1.29&#8211;3.86)</td><td align="center" valign="top" rowspan="1" colspan="1">1.79 (0.99&#8211;3.22)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypospadias</td><td align="center" valign="top" rowspan="1" colspan="1">12,513</td><td align="center" valign="top" rowspan="1" colspan="1">30.2</td><td align="center" valign="top" rowspan="1" colspan="1">88</td><td align="center" valign="top" rowspan="1" colspan="1">40.7</td><td align="center" valign="top" rowspan="1" colspan="1">12,425</td><td align="center" valign="top" rowspan="1" colspan="1">30.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.35 (1.09&#8211;1.66)</td><td align="center" valign="top" rowspan="1" colspan="1">1.23 (1.03&#8211;1.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Transverse limb deficiency</td><td align="center" valign="top" rowspan="1" colspan="1">1389</td><td align="center" valign="top" rowspan="1" colspan="1">3.4</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td><td align="center" valign="top" rowspan="1" colspan="1">1376</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.80 (1.04&#8211;3.11)</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (0.71&#8211;2.25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Renal agenesis &amp; stenosis</td><td align="center" valign="top" rowspan="1" colspan="1">2064</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">3.7</td><td align="center" valign="top" rowspan="1" colspan="1">2056</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.37&#8211;1.48)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.31&#8211;1.28)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anorectal atresia &amp; stenosis</td><td align="center" valign="top" rowspan="1" colspan="1">1669</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">7.4</td><td align="center" valign="top" rowspan="1" colspan="1">1633</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">1.87 (1.14&#8211;3.05)</td><td align="center" valign="top" rowspan="1" colspan="1">1.60 (0.95&#8211;2.70)</td></tr></tbody></table><table-wrap-foot id="bdr22456-ntgp-0003"><fn id="bdr22456-note-0007"><label>*</label><p>Adjusted risk ratio (aRR) for all or specified subtype of anomaly is estimated after adjusting for maternal age, parity, multiple gestation, chronic condition or illness, pregestational diabetes, substance use disorders, including tobacco, alcohol, cannabinoids, psychostimulants, inhalant, and psychoactive or psychotropic substances, rural (versus urban) residence, newborn sex, and 5&#8208;year period of birth using the categories presented in Table&#160;<xref rid="bdr22456-tbl-0001" ref-type="table">1</xref>.</p></fn></table-wrap-foot></table-wrap><p>E&#8208;values for associations between specified CAs and maternal prenatal diagnosis of OUD are included in Table&#160;<xref rid="bdr22456-supitem-0001" ref-type="supplementary-material">S3</xref>. These E&#8208;values suggested that relatively strong confounding assumptions would be needed to eliminate the associations between prenatal exposure to maternal OUDs and specific CAs in offspring. For example, E&#8208;values for the association between maternal prenatal OUD and the risk of congenital microcephaly (<italic toggle="yes">E</italic>&#8201;=&#8201;9.87 and lower 95% confidence bound 7.62), the risk of cleft palate (8.89 and 6.88, respectively), the risk of atrial septal defect (5.73 and 5.13, respectively), the risk of ventricular septal defect (4.46 and 3.74, respectively), and the risk of coarctation of the aorta (3.87 and 2.37, respectively).</p></sec><sec sec-type="discussion" id="bdr22456-sec-0008"><label>4</label><title>Discussion</title><p>Overall, our analysis demonstrates that diagnosed maternal OUD may be associated with certain CAs in infants, highlighting the need for continued surveillance and support to mitigate maternal substance use disorder, especially with increasing trends of opioid use in Canada. The prevalence of diagnosed prenatal OUD was relatively low (0.52%), but likely under&#8208;ascertained (Cook&#160;<xref rid="bdr22456-bib-0005" ref-type="bibr">2022</xref>). These exposures, although affecting only a small proportion of pregnancies/births, have the potential to affect thousands of births across Canada, reflect possibly life&#8208;threatening and long&#8208;lasting health outcomes, and are of serious public health concern.</p><p>Our study examined the relationship between prenatal OUD diagnosis and CAs; recent studies focusing on maternal opioid use and CAs have examined prescription opioid exposure by trimester (Wen et&#160;al.&#160;<xref rid="bdr22456-bib-0035" ref-type="bibr">2021</xref>), NAS and CAs (Bhatt et&#160;al.&#160;<xref rid="bdr22456-bib-0002" ref-type="bibr">2022</xref>), the treatment of OUD during pregnancy, the risk of CAs (Suarez et&#160;al.&#160;<xref rid="bdr22456-bib-0030" ref-type="bibr">2022</xref>, <xref rid="bdr22456-bib-0029" ref-type="bibr">2024</xref>), and other adverse neonatal outcomes (Piske et&#160;al.&#160;<xref rid="bdr22456-bib-0023" ref-type="bibr">2021</xref>). A meta&#8208;analysis of cohort studies examining opioid exposure during pregnancy and the risk of congenital malformations found that opioid exposure during pregnancy was associated with a 30% increased risk of congenital malformations overall (Wang et&#160;al.&#160;<xref rid="bdr22456-bib-0033" ref-type="bibr">2022</xref>). However, several studies have found no such association (Greig et&#160;al.&#160;<xref rid="bdr22456-bib-0008" ref-type="bibr">2012</xref>; K&#228;ll&#233;n et&#160;al.&#160;<xref rid="bdr22456-bib-0012" ref-type="bibr">2013</xref>) and few studies have examined the risk of CAs associated with diagnosed prenatal opioid disorder. In a small cohort study of Canadian women being treated for OUD (<italic toggle="yes">n</italic>&#8201;=&#8201;45 mother&#8211;baby dyads), 17.8% of neonates were identified as having a CA (including bilateral hydroceles, Tetralogy of Fallot, right&#8208;hand malformation, hypospadias, ankyloglossia, and ventricular septal defect, among others) (Miller et&#160;al.&#160;<xref rid="bdr22456-bib-0019" ref-type="bibr">2019</xref>). It is possible that other factors associated with OUD can influence CAs and other fetal outcomes, such as opioid substitution treatment, frequency and severity of prenatal opioid use, and socio&#8208;economic status. Future studies should examine the impact of these factors on the relationship between prenatal OUD diagnosis and CAs.</p><p>In our study, there was potential for non&#8208;differential exposure misclassification, representing only diagnosed cases of maternal OUD during pregnancy, with babies affected by CAs being more likely to be coded as having exposure to a substance in delivery records than those without. There is also the possibility of differential classification of the outcome, in which birthing persons diagnosed with OUD during delivery may be more likely to have their infants coded for a CA. Similarly, only 0.52% of births in our study cohort were identified as being to those with a prenatal OUD diagnosis when other studies have estimated that diagnosed OUD is present in 0.82% of labor and delivery hospitalizations (Hirai et&#160;al.&#160;<xref rid="bdr22456-bib-0010" ref-type="bibr">2021</xref>).</p><p>This study had both strengths and limitations. Our study responds to the need to generate more evidence on the impacts of OUD during pregnancy. Although CAs are generally considered rare events, our study design using a large, population&#8208;based, administrative dataset with strong internal validity (Joseph et&#160;al.&#160;<xref rid="bdr22456-bib-0011" ref-type="bibr">2009</xref>) allowed us to identify nearly all cases of CAs during the labor and delivery hospitalizations and neonatal readmissions over the study period. Furthermore, it provided us with statistical power to estimate associations and to control for potential confounders. The E&#8208;values obtained from our sensitivity analysis also suggest that unmeasured confounding is unlikely to account for the associations with specific CAs. Our study data also provide updated estimates of diagnosed OUD during pregnancy across the study period.</p><p>Because maternal substance use can be highly stigmatized, it is important to recognize potential limitations of the measurement of maternal substance use. First, our study relied on the DAD for the measurement of both exposure and outcome, and OUD may have been missed or only reported as OUD even if polydrug use was present. Second, our use of data from the DAD only at the labor and delivery hospitalization affected examination of (i) timing of exposure, as we focused only on the labor and delivery hospitalization as the sole point of exposure measurement and we were not able to estimate dose or frequency of exposure, which might also have affected fetal development, and (ii) outcome measurement, as CAs that were not identified at this time were not captured in our analysis. Third, as this study involved secondary analysis of an administrative dataset, it is possible that exposures or outcomes could be miscoded (e.g., it is possible that the use of P96.1 to code maternal opioid exposure may have caused some false positives as some neonates with withdrawal symptoms who are coded with P96.1 may be actually due to other &#8220;drugs of addiction&#8221; besides opioids). Finally, our use of an administrative database limited our inclusion of potential confounders (e.g., socioeconomic status) and treatment for OUD in our analyses. Although our sensitivity analysis indicated that a high level of unmeasured confounding would be necessary to fully nullify the associations observed in our study (indicating the robustness of our findings) (Van der and Ding,&#160;<xref rid="bdr22456-bib-0034" ref-type="bibr">2017</xref>), caution should be taken when interpreting these results. Prospective studies are needed to examine these potential confounders and the effects that timing, dose, or frequency of prenatal opioid use might have on birth outcomes (Saleh Gargari et&#160;al.&#160;<xref rid="bdr22456-bib-0027" ref-type="bibr">2012</xref>). Future studies should also examine the impact of prenatal exposure to maternal opioid treatment on the development of CAs.</p></sec><sec sec-type="conclusions" id="bdr22456-sec-0009"><label>5</label><title>Conclusions</title><p>Our study examined the relationship between prenatal OUD diagnosis and the risk of CAs in the offspring. Our findings suggest that prenatal OUD diagnosis may be associated with certain CAs in newborns; however, future analysis examining the impact of substance use patterns, substance use treatment, and other potential confounders is necessary and can provide estimates that more accurately represent the true relationship between prenatal opioid exposure and CAs. Our study contributes important information for clinicians and other service providers to support healthy pregnancy and fetal development. In accordance with recommendations from the Society of Obstetricians and Gynecologists of Canada (Ordean et&#160;al.&#160;<xref rid="bdr22456-bib-0021" ref-type="bibr">2017</xref>), clinicians should be prepared to screen birthing persons for substance use during pregnancy, provide guidance regarding the risks of substance use during pregnancy, and make appropriate referrals.</p></sec><sec id="bdr22456-sec-0011"><title>Author Contributions</title><p>Liu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></sec><sec id="bdr22456-sec-0012"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="bdr22456-sec-0013"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="bdr22456-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S1.</bold> International Classification of Disease Codes for maternal risk factors, conditions or illnesses.</p><p>
<bold>Table&#160;S2</bold>. International Classification of Disease Codes: Infant Congenital Anomalies.</p><p>
<bold>Table&#160;S3</bold>. E&#8208;values expressing the required risk ratio for any unmeasured confounder to overcome the observed association of specific congenital anomalies with prenatal diagnosis of opioid use disorder.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BDR2-117-e2456-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="bdr22456-sec-0010"><title>Acknowledgments</title><p>The authors thank Dr. Nathalie Auger (University of Montreal, Montreal, Quebec, Canada), Mihaela Gheorghe, Wei Luo, and Dr. Chantal Nelson (Public Health Agency of Canada, Ottawa, Ontario, Canada) for comment on earlier analysis and the Canadian Institute for Health Information (CIHI) for providing access to the Discharge Abstract Database at the Public Health Agency of Canada.</p></ack><sec sec-type="data-availability" id="bdr22456-sec-0015"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from Canadian Institute for Health Information. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the author(s) with the permission of Canadian Institute for Health Information.</p></sec><ref-list content-type="cited-references" id="bdr22456-bibl-0001"><title>References</title><ref id="bdr22456-bib-0001"><mixed-citation publication-type="journal" id="bdr22456-cit-0001"><string-name name-style="western"><surname>Belzak</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Halverson</surname></string-name>. <year>2018</year>. &#8220;<article-title>Evidence Synthesis &#8208; The Opioid Crisis in Canada: A National Perspective</article-title>.&#8221; <source>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</source><volume>38</volume>, no. <issue>6</issue>: <fpage>224</fpage>&#8211;<lpage>233</lpage>.<pub-id pub-id-type="pmid">29911818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.24095/hpcdp.38.6.02</pub-id><pub-id pub-id-type="pmcid">PMC6034966</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0002"><mixed-citation publication-type="journal" id="bdr22456-cit-0002"><string-name name-style="western"><surname>Bhatt</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ampem&#8208;Darko</surname></string-name>, <string-name name-style="western"><given-names>G. A.</given-names><surname>Cudjoe</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Association Between Neonatal Abstinence Syndrome and Congenital Anomalies in the United States</article-title>.&#8221; <source>American Journal of Perinatology</source><volume>41</volume>: <elocation-id>e1023&#8211;e1029</elocation-id>. <pub-id pub-id-type="doi">10.1055/s-0042-1759864</pub-id>.<pub-id pub-id-type="pmid">36572036</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0003"><mixed-citation publication-type="journal" id="bdr22456-cit-0003"><string-name name-style="western"><surname>Brogly</surname>, <given-names>S. B.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Lajkosz</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Infants Born to Opioid&#8208;Dependent Women in Ontario, 2002&#8208;2014</article-title>.&#8221; <source>Journal of Obstetrics and Gynaecology Canada: JOGC = Journal d'obstetrique et Gynecologie Du Canada: JOGC</source><volume>39</volume>, no. <issue>3</issue>: <fpage>157</fpage>&#8211;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.jogc.2016.11.009</pub-id>.<pub-id pub-id-type="pmid">28343557</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0004"><mixed-citation publication-type="journal" id="bdr22456-cit-0004"><string-name name-style="western"><surname>Camden</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>J. G.</given-names><surname>Ray</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>To</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Gomes</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bai</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Guttmann</surname></string-name>. <year>2021</year>. &#8220;<article-title>Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014&#8208;2019</article-title>.&#8221; <source>JAMA Network Open</source><volume>4</volume>, no. <issue>2</issue>: <elocation-id>e2037388</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.37388</pub-id>.<pub-id pub-id-type="pmid">33595660</pub-id><pub-id pub-id-type="pmcid">PMC7890532</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0005"><mixed-citation publication-type="journal" id="bdr22456-cit-0005"><string-name name-style="western"><surname>Cook</surname>, <given-names>J. L.</given-names></string-name><year>2022</year>. &#8220;<article-title>Epidemiology of Opioid Use in Pregnancy</article-title>.&#8221; <source>Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology</source><volume>85</volume>: <fpage>12</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2022.07.008</pub-id>.<pub-id pub-id-type="pmid">36045026</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0006"><mixed-citation publication-type="journal" id="bdr22456-cit-0006"><string-name name-style="western"><surname>Corsi</surname>, <given-names>D. J.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Hsu</surname></string-name>, <string-name name-style="western"><given-names>D. B.</given-names><surname>Fell</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Wen</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Walker</surname></string-name>. <year>2020</year>. &#8220;<article-title>Association of Maternal Opioid Use in Pregnancy With Adverse Perinatal Outcomes in Ontario, Canada, From 2012 to 2018</article-title>.&#8221; <source>JAMA Network Open</source><volume>3</volume>, no. <issue>7</issue>: <elocation-id>e208256</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8256</pub-id>.<pub-id pub-id-type="pmid">32725246</pub-id><pub-id pub-id-type="pmcid">PMC12064095</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0007"><mixed-citation publication-type="journal" id="bdr22456-cit-0007"><string-name name-style="western"><surname>Fischer</surname>, <given-names>B.</given-names></string-name><year>2023</year>. &#8220;<article-title>The Continuous Opioid Death Crisis in Canada: Changing Characteristics and Implications for Path Options Forward</article-title>.&#8221; <source>Lancet Regional Health</source><volume>19</volume>: <elocation-id>100437</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.lana.2023.100437</pub-id>.<pub-id pub-id-type="pmid">36950034</pub-id><pub-id pub-id-type="pmcid">PMC10025405</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0008"><mixed-citation publication-type="journal" id="bdr22456-cit-0008"><string-name name-style="western"><surname>Greig</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ash</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Douiri</surname></string-name>. <year>2012</year>. &#8220;<article-title>Maternal and Neonatal Outcomes Following Methadone Substitution During Pregnancy</article-title>.&#8221; <source>Archives of Gynecology and Obstetrics</source><volume>286</volume>, no. <issue>4</issue>: <fpage>843</fpage>&#8211;<lpage>851</lpage>. <pub-id pub-id-type="doi">10.1007/s00404-012-2372-9</pub-id>.<pub-id pub-id-type="pmid">22584603</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0009"><mixed-citation publication-type="miscellaneous" id="bdr22456-cit-0009"><collab collab-type="authors">Health Canada</collab>
. <year>2021</year>. <article-title>&#8220;Canadian Alcohol and Drugs Survey (CADS): Summary of results for 2019 [Surveys].&#8221;</article-title></mixed-citation></ref><ref id="bdr22456-bib-0010"><mixed-citation publication-type="journal" id="bdr22456-cit-0010"><string-name name-style="western"><surname>Hirai</surname>, <given-names>A. H.</given-names></string-name>, <string-name name-style="western"><given-names>J. Y.</given-names><surname>Ko</surname></string-name>, <string-name name-style="western"><given-names>P. L.</given-names><surname>Owens</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Stocks</surname></string-name>, and <string-name name-style="western"><given-names>S. W.</given-names><surname>Patrick</surname></string-name>. <year>2021</year>. &#8220;<article-title>Neonatal Abstinence Syndrome and Maternal Opioid&#8208;Related Diagnoses in the US, 2010&#8208;2017</article-title>.&#8221; <source>JAMA</source><volume>325</volume>, no. <issue>2</issue>: <fpage>146</fpage>&#8211;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.24991</pub-id>.<pub-id pub-id-type="pmid">33433576</pub-id><pub-id pub-id-type="pmcid">PMC7804920</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0011"><mixed-citation publication-type="journal" id="bdr22456-cit-0011"><string-name name-style="western"><surname>Joseph</surname>, <given-names>K. S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fahey</surname></string-name>, and <collab collab-type="authors">Canadian Perinatal Surveillance System</collab>
. <year>2009</year>. &#8220;<article-title>Validation of Perinatal Data in the Discharge Abstract Database of the Canadian Institute for Health Information</article-title>.&#8221; <source>Chronic Diseases in Canada</source><volume>29</volume>, no. <issue>3</issue>: <fpage>96</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">19527567</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0012"><mixed-citation publication-type="journal" id="bdr22456-cit-0012"><string-name name-style="western"><surname>K&#228;ll&#233;n</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Borg</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Reis</surname></string-name>. <year>2013</year>. &#8220;<article-title>The Use of Central Nervous System Active Drugs During Pregnancy</article-title>.&#8221; <source>Pharmaceuticals (Basel, Switzerland)</source><volume>6</volume>, no. <issue>10</issue>: <fpage>1221</fpage>&#8211;<lpage>1286</lpage>. <pub-id pub-id-type="doi">10.3390/ph6101221</pub-id>.<pub-id pub-id-type="pmid">24275849</pub-id><pub-id pub-id-type="pmcid">PMC3817603</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0013"><mixed-citation publication-type="journal" id="bdr22456-cit-0013"><string-name name-style="western"><surname>Lind</surname>, <given-names>J. N.</given-names></string-name>, <string-name name-style="western"><given-names>J. D.</given-names><surname>Interrante</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Ailes</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review</article-title>.&#8221; <source>Pediatrics</source><volume>139</volume>, no. <issue>6</issue>: <elocation-id>e20164131</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2016-4131</pub-id>.<pub-id pub-id-type="pmid">28562278</pub-id><pub-id pub-id-type="pmcid">PMC5561453</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0014"><mixed-citation publication-type="journal" id="bdr22456-cit-0014"><string-name name-style="western"><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Evans</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Boutin</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Time Trends, Geographic Variation and Risk Factors for Gastroschisis in Canada: A Population&#8208;Based Cohort Study 2006&#8208;2017</article-title>.&#8221; <source>Paediatric and Perinatal Epidemiology</source><volume>35</volume>, no. <issue>6</issue>: <fpage>664</fpage>&#8211;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1111/ppe.12800</pub-id>.<pub-id pub-id-type="pmid">34472132</pub-id><pub-id pub-id-type="pmcid">PMC9291817</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0015"><mixed-citation publication-type="journal" id="bdr22456-cit-0015"><string-name name-style="western"><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Evans</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>MacFarlane</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Association of Maternal Risk Factors With the Recent Rise of Neural Tube Defects in Canada</article-title>.&#8221; <source>Paediatric and Perinatal Epidemiology</source><volume>33</volume>, no. <issue>2</issue>: <fpage>145</fpage>&#8211;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1111/ppe.12543</pub-id>.<pub-id pub-id-type="pmid">30920008</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0016"><mixed-citation publication-type="journal" id="bdr22456-cit-0016"><string-name name-style="western"><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rouleau</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Le&#243;n</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sauve</surname></string-name>, <string-name name-style="western"><given-names>K. S.</given-names><surname>Joseph</surname></string-name>, and <string-name name-style="western"><given-names>J. G.</given-names><surname>Ray</surname></string-name>. <year>2015</year>. &#8220;<article-title>System, C. P. S. Impact of Pre&#8208;Pregnancy Diabetes Mellitus on Congenital Anomalies, Canada</article-title>.&#8221; <source>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</source><volume>35</volume>, no. <issue>5</issue>: <fpage>79</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">26186019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.24095/hpcdp.35.5.01</pub-id><pub-id pub-id-type="pmcid">PMC4910455</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0017"><mixed-citation publication-type="journal" id="bdr22456-cit-0017"><string-name name-style="western"><surname>Liu</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>S. W.</given-names><surname>Wen</surname></string-name>. <year>1999</year>. &#8220;<article-title>Development of Record Linkage of Hospital Discharge Data for the Study of Neonatal Readmission</article-title>.&#8221; <source>Chronic Diseases in Canada</source><volume>20</volume>, no. <issue>2</issue>: <fpage>77</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">10455039</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0018"><mixed-citation publication-type="journal" id="bdr22456-cit-0018"><string-name name-style="western"><surname>Merhar</surname>, <given-names>S. L.</given-names></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Kline</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Braimah</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Prenatal Opioid Exposure Is Associated With Smaller Brain Volumes in Multiple Regions</article-title>.&#8221; <source>Pediatric Research</source><volume>90</volume>, no. <issue>2</issue>: <fpage>397</fpage>&#8211;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1038/s41390-020-01265-w</pub-id>.<pub-id pub-id-type="pmid">33177677</pub-id><pub-id pub-id-type="pmcid">PMC8110593</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0019"><mixed-citation publication-type="journal" id="bdr22456-cit-0019"><string-name name-style="western"><surname>Miller</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Grynspan</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Gaudet</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Maternal and Neonatal Characteristics of a Canadian Urban Cohort Receiving Treatment for Opioid Use Disorder During Pregnancy</article-title>.&#8221; <source>Journal of Developmental Origins of Health and Disease</source><volume>10</volume>, no. <issue>1</issue>: <fpage>132</fpage>&#8211;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1017/S2040174418000478</pub-id>.<pub-id pub-id-type="pmid">30113278</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0020"><mixed-citation publication-type="journal" id="bdr22456-cit-0020"><string-name name-style="western"><surname>N&#248;rgaard</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Nielsson</surname></string-name>, and <string-name name-style="western"><given-names>U.</given-names><surname>Heide&#8208;J&#248;rgensen</surname></string-name>. <year>2015</year>. &#8220;<article-title>Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population&#8208;Based Study</article-title>.&#8221; <source>Substance Abuse: Research and Treatment</source><volume>9</volume>, no. <issue>Suppl 2</issue>: <fpage>5</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.4137/SART.S23547</pub-id>.<pub-id pub-id-type="pmcid">PMC4599593</pub-id><pub-id pub-id-type="pmid">26512202</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0021"><mixed-citation publication-type="journal" id="bdr22456-cit-0021"><string-name name-style="western"><surname>Ordean</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wong</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Graves</surname></string-name>. <year>2017</year>. &#8220;<article-title>No. 349&#8208;Substance use in pregnancy</article-title>.&#8221; <source>Journal of Obstetrics and Gynaecology Canada</source><volume>39</volume>, no. <issue>10</issue>: <fpage>922</fpage>&#8211;<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1016/j.jogc.2017.04.028</pub-id>.<pub-id pub-id-type="pmid">28935057</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0022"><mixed-citation publication-type="journal" id="bdr22456-cit-0022"><string-name name-style="western"><surname>Patrick</surname>, <given-names>S. W.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Dudley</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Martin</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Prescription Opioid Epidemic and Infant Outcomes</article-title>.&#8221; <source>Pediatrics</source><volume>135</volume>, no. <issue>5</issue>: <fpage>842</fpage>&#8211;<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-3299</pub-id>.<pub-id pub-id-type="pmid">25869370</pub-id><pub-id pub-id-type="pmcid">PMC4411781</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0023"><mixed-citation publication-type="journal" id="bdr22456-cit-0023"><string-name name-style="western"><surname>Piske</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Homayra</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Min</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Opioid Use Disorder and Perinatal Outcomes</article-title>.&#8221; <source>Pediatrics</source><volume>148</volume>, no. <issue>4</issue>: <elocation-id>e2021050279</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2021-050279</pub-id>.<pub-id pub-id-type="pmid">34479983</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0024"><mixed-citation publication-type="journal" id="bdr22456-cit-0024"><string-name name-style="western"><surname>Plouffe</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Grywacheski</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Nelson</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Orpana</surname></string-name>. <year>2023</year>. &#8220;<article-title>Neonatal Abstinence Syndrome Hospitalizations in Canada: A Descriptive Study</article-title>.&#8221; <source>Canadian Journal of Public Health</source><volume>114</volume>, no. <issue>2</issue>: <fpage>277</fpage>&#8211;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.17269/s41997-022-00726-5</pub-id>.<pub-id pub-id-type="pmid">36482143</pub-id><pub-id pub-id-type="pmcid">PMC9734797</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0025"><mixed-citation publication-type="journal" id="bdr22456-cit-0025"><collab collab-type="authors">Public Health Agency of Canada</collab>
. <year>2013</year>. &#8220;<article-title>Congenital Anomalies in Canada 2013: A Perinatal Health Surveillance Report</article-title>.&#8221; <source>Public Health Agency of Canada</source>.</mixed-citation></ref><ref id="bdr22456-bib-0026"><mixed-citation publication-type="journal" id="bdr22456-cit-0026"><string-name name-style="western"><surname>Ramage</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Grabowska</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Silversides</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Quan</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Metcalfe</surname></string-name>. <year>2019</year>. &#8220;<article-title>Association of Adult Congenital Heart Disease With Pregnancy, Maternal, and Neonatal Outcomes</article-title>.&#8221; <source>JAMA Network Open</source><volume>2</volume>, no. <issue>5</issue>: <elocation-id>e193667</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.3667</pub-id>.<pub-id pub-id-type="pmid">31074818</pub-id><pub-id pub-id-type="pmcid">PMC6512464</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0027"><mixed-citation publication-type="journal" id="bdr22456-cit-0027"><string-name name-style="western"><surname>Saleh Gargari</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Fallahian</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Haghighi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hosseinnezhad&#8208;Yazdi</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Dashti</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Dolan</surname></string-name>. <year>2012</year>. &#8220;<article-title>Maternal and Neonatal Complications of Substance Abuse in Iranian Pregnant Women</article-title>.&#8221; <source>Acta Medica Iranica</source><volume>50</volume>, no. <issue>6</issue>: <fpage>411</fpage>&#8211;<lpage>416</lpage>.<pub-id pub-id-type="pmid">22837120</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0028"><mixed-citation publication-type="journal" id="bdr22456-cit-0028"><string-name name-style="western"><surname>Short</surname>, <given-names>T. D.</given-names></string-name><year>2019</year>. &#8220;<article-title>Gastroschisis Trends and Ecologic Link to Opioid Prescription Rates&#8212;United States, 2006&#8211;2015</article-title>.&#8221; <source>MMWR. Morbidity and Mortality Weekly Report</source><volume>68</volume>, no. <issue>2</issue>: <fpage>31</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6802a2</pub-id>.<pub-id pub-id-type="pmid">30653484</pub-id><pub-id pub-id-type="pmcid">PMC6336188</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0029"><mixed-citation publication-type="journal" id="bdr22456-cit-0029"><string-name name-style="western"><surname>Suarez</surname>, <given-names>E. A.</given-names></string-name>, <string-name name-style="western"><given-names>B. T.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Straub</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations</article-title>.&#8221; <source>JAMA Internal Medicine</source><volume>184</volume>, no. <issue>3</issue>: <fpage>242</fpage>&#8211;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2023.6986</pub-id>.<pub-id pub-id-type="pmid">38252426</pub-id><pub-id pub-id-type="pmcid">PMC10804281</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0030"><mixed-citation publication-type="journal" id="bdr22456-cit-0030"><string-name name-style="western"><surname>Suarez</surname>, <given-names>E. A.</given-names></string-name>, <string-name name-style="western"><given-names>K. F.</given-names><surname>Huybrechts</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Straub</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Buprenorphine Versus Methadone for Opioid Use Disorder in Pregnancy</article-title>.&#8221; <source>New England Journal of Medicine</source><volume>387</volume>, no. <issue>22</issue>: <fpage>2033</fpage>&#8211;<lpage>2044</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2203318</pub-id>.<pub-id pub-id-type="pmid">36449419</pub-id><pub-id pub-id-type="pmcid">PMC9873239</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0031"><mixed-citation publication-type="journal" id="bdr22456-cit-0031"><string-name name-style="western"><surname>Turner</surname>, <given-names>S. D.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Gomes</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Camacho</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Neonatal Opioid Withdrawal and Antenatal Opioid Prescribing</article-title>.&#8221; <source>CMAJ Open</source><volume>3</volume>, no. <issue>1</issue>: <fpage>E55</fpage>&#8211;<lpage>E61</lpage>. <pub-id pub-id-type="doi">10.9778/cmajo.20140065</pub-id>.<pub-id pub-id-type="pmcid">PMC4382031</pub-id><pub-id pub-id-type="pmid">25844370</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0032"><mixed-citation publication-type="journal" id="bdr22456-cit-0032"><string-name name-style="western"><surname>Viteri</surname>, <given-names>O. A.</given-names></string-name>, <string-name name-style="western"><given-names>E. E.</given-names><surname>Soto</surname></string-name>, <string-name name-style="western"><given-names>R. O.</given-names><surname>Bahado&#8208;Singh</surname></string-name>, <string-name name-style="western"><given-names>C. W.</given-names><surname>Christensen</surname></string-name>, <string-name name-style="western"><given-names>S. P.</given-names><surname>Chauhan</surname></string-name>, and <string-name name-style="western"><given-names>B. M.</given-names><surname>Sibai</surname></string-name>. <year>2015</year>. &#8220;<article-title>Fetal Anomalies and Long&#8208;Term Effects Associated With Substance Abuse in Pregnancy: A Literature Review</article-title>.&#8221; <source>American Journal of Perinatology</source><volume>32</volume>, no. <issue>5</issue>: <fpage>405</fpage>&#8211;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1055/s-0034-1393932</pub-id>.<pub-id pub-id-type="pmid">25486291</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0033"><mixed-citation publication-type="journal" id="bdr22456-cit-0033"><string-name name-style="western"><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Tang</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Feng</surname></string-name>. <year>2022</year>. &#8220;<article-title>Opioid Exposure During Pregnancy and the Risk of Congenital Malformation: A Meta&#8208;Analysis of Cohort Studies</article-title>.&#8221; <source>BMC Pregnancy and Childbirth</source><volume>22</volume>: <fpage>401</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-022-04733-9</pub-id>.<pub-id pub-id-type="pmid">35546223</pub-id><pub-id pub-id-type="pmcid">PMC9097072</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0034"><mixed-citation publication-type="journal" id="bdr22456-cit-0034"><string-name name-style="western"><surname>Van der Weele</surname>, <given-names>T. J.</given-names></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Ding</surname></string-name>. <year>2017</year>. &#8220;<article-title>Sensitivity Analysis in Observational Research: Introducing the E&#8208;Value</article-title>.&#8221; <source>Annals of Internal Medicine</source><volume>167</volume>, no. <issue>4</issue>: <fpage>268</fpage>&#8211;<lpage>274</lpage>. <pub-id pub-id-type="doi">10.7326/M16-2607</pub-id>.<pub-id pub-id-type="pmid">28693043</pub-id></mixed-citation></ref><ref id="bdr22456-bib-0035"><mixed-citation publication-type="journal" id="bdr22456-cit-0035"><string-name name-style="western"><surname>Wen</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Belviso</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Murray</surname></string-name>, <string-name name-style="western"><given-names>A. K.</given-names><surname>Lewkowitz</surname></string-name>, <string-name name-style="western"><given-names>K. E.</given-names><surname>Ward</surname></string-name>, and <string-name name-style="western"><given-names>K. J.</given-names><surname>Meador</surname></string-name>. <year>2021</year>. &#8220;<article-title>Association of gestational opioid exposure and risk of major and minor congenital malformations</article-title>.&#8221; <source>JAMA network open</source><volume>4</volume>, no. <issue>4</issue>: <elocation-id>e215708</elocation-id>.<pub-id pub-id-type="pmid">33847750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.5708</pub-id><pub-id pub-id-type="pmcid">PMC8044730</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>